文献速递垂体与肾上腺疾病

奥唑司他治疗库欣病的随机试验

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

LINC 4 是一项 III 期多中心试验,比较奥唑司他与安慰剂治疗库欣病。第 12 周时,奥唑司他组 77% 患者平均尿游离皮质醇(mUFC)≤ 正常上限(ULN),安慰剂组仅 8%(比值比 43.4;95%CI 7.1,343.2;P < 0.0001)。第 36 周时 81% 患者维持 mUFC ≤ ULN,安全性良好。

要点

  • 奥唑司他组第 12 周 77% 达到 mUFC ≤ ULN,安慰剂组 8%(P < 0.0001)。
  • 第 36 周时 81%(95%CI 69.9,89.1)的患者维持 mUFC ≤ ULN。
  • 安慰剂对照期常见不良事件为食欲下降、关节痛和恶心。

核心结论

  • 奥唑司他快速使大多数库欣病患者的 mUFC 恢复正常,并在整个研究期间维持该效应,安全性良好。

研究设计与样本

  • LINC 4 为 III 期多中心试验,包括初始 12 周随机双盲安慰剂对照期(奥唑司他:安慰剂=2:1)和随后 36 周开放标签治疗期(NCT02697734)。
  • 纳入 18-75 岁确诊库欣病且 mUFC ≥ 1.3 倍 ULN 的成人患者,共 73 例接受随机治疗(奥唑司他 n=48,安慰剂 n=25)。

主要发现

  • 第 12 周时,奥唑司他组 77% 患者 mUFC ≤ ULN,安慰剂组 8%,比值比 43.4(95%CI 7.1,343.2;P < 0.0001)。
  • 第 36 周时,81%(95%CI 69.9,89.1)的患者 mUFC ≤ ULN。
  • 安慰剂对照期最常见不良事件(奥唑司他 vs 安慰剂):食欲下降 37.5% vs 16.0%,关节痛 35.4% vs 8.0%,恶心 31.3% vs 12.0%。

关键数值与推荐

  • 主要终点为第 12 周随机患者中 mUFC ≤ ULN 的比例:奥唑司他 77% vs 安慰剂 8%(P < 0.0001)。
  • 关键次要终点为第 36 周(开放标签奥唑司他治疗 24 周后)mUFC ≤ ULN 的比例:81%(95%CI 69.9,89.1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Cushing disease, a chronic hypercortisolism disorder, is associated with considerable morbidity and mortality. Normalizing cortisol production is the primary treatment goal. OBJECTIVE: We aimed to evaluate the safety and efficacy of osilodrostat, a potent, orally available 11βhydroxylase inhibitor, compared with placebo in patients with Cushing disease. METHODS: LINC 4 was a phase III, multicenter trial comprising an initial 12-week, randomized, double-blind, placebo-controlled (osilodrostat:placebo, 2:1) period followed by a 36-week, open-label treatment period (NCT02697734). Adult patients (aged 18-75 years) with confirmed Cushing disease and mean urinary free cortisol (mUFC) excretion ≥ 1.3 times the upper limit of normal (ULN) were eligible. The primary endpoint was the proportion of randomized patients with mUFC ≤ ULN at week 12. The key secondary endpoint was the proportion achieving mUFC ≤ ULN at week 36 (after 24 weeks' open-label osilodrostat). RESULTS: Seventy-three patients (median age, 39 years [range, 19-67]; mean/median mUFC, 3.1 × ULN/2.5 × ULN) received randomized treatment with osilodrostat (n = 48) or placebo (n = 25). At week 12, significantly more osilodrostat (77%) than placebo (8%) patients achieved mUFC ≤ ULN (odds ratio 43.4; 95% CI 7.1, 343.2; P < 0.0001). Response was maintained at week 36, when 81% (95% CI 69.9, 89.1) of all patients achieved mUFC ≤ ULN. The most common adverse events during the placebo-controlled period (osilodrostat vs placebo) were decreased appetite (37.5% vs 16.0%), arthralgia (35.4% vs 8.0%), and nausea (31.3% vs 12.0%). CONCLUSION: Osilodrostat rapidly normalized mUFC excretion in most patients with Cushing disease and maintained this effect throughout the study. The safety profile was favorable.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gadelha M, Bex M, Feelders RA, et al. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab. 2022. PMID: 35325149. doi:10.1210/clinem/dgac178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。